Previous close | 112.52 |
Open | 113.00 |
Bid | 113.54 x 900 |
Ask | 113.57 x 800 |
Day's range | 112.60 - 114.48 |
52-week range | 83.05 - 119.65 |
Volume | |
Avg. volume | 7,549,538 |
Market cap | 288.253B |
Beta (5Y monthly) | 0.36 |
PE ratio (TTM) | 21.85 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.92 (2.63%) |
Ex-dividend date | 14 Jun 2023 |
1y target est | N/A |
RAHWAY, N.J., June 03, 2023--KEYTRUDA Plus Chemo Before Surgery and as a Single Agent After Surgery Reduced Risk of EFS by 42% Vs Pre-Operative Chemo in Stage II, IIIA, IIIB NSCLC
RAHWAY, N.J. & KINGSTON, Ontario, June 03, 2023--KEYTRUDA Plus Chemo Significantly Improved Overall Survival Versus Chemo Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
RAHWAY, N.J., June 01, 2023--FDA Approves LYNPARZA Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated mCRPC
RAHWAY, N.J. & NUTLEY, N.J., May 25, 2023--KEYTRUDA® Plus LENVIMA® Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC
RAHWAY, N.J., May 23, 2023--Merck Announces Third-Quarter 2023 Dividend
RAHWAY, N.J., May 15, 2023--Merck ASCO Curtain Raiser
RAHWAY, N.J., May 03, 2023--Merck to Participate in Bank of America Securities 2023 Healthcare Conference
RAHWAY, N.J., April 28, 2023--Update on FDA Advisory Committee Vote on LYNPARZA Plus Abiraterone and Prednisone or Prednisolone in First-Line mCRPC
RAHWAY, N.J., April 27, 2023--Merck Announces First-Quarter 2023 Financial Results
RAHWAY, N.J., April 16, 2023--Merck’s KEYTRUDA® Plus Chemotherapy Significantly Improved OS Compared to Chemotherapy Alone in Patients With Advanced or Unresectable BTC
RAHWAY, N.J. & SAN DIEGO, April 16, 2023--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Prometheus Biosciences, Inc. ("Prometheus") (Nasdaq: RXDX) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion.
RAHWAY, N.J., April 13, 2023--KEYTRUDA KEYNOTE-859 Filing Acceptance
RAHWAY, N.J. & NUTLEY, N.J., April 07, 2023--Merck and Eisai Provide Update on Phase 3 Trials of KEYTRUDA plus LENVIMA In Certain Patients With Advanced Melanoma and Metastatic Colorectal Cancer
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
RAHWAY, N.J., April 03, 2023--FDA Approves KEYTRUDA in Combination With Padcev for First-Line Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Cancer
RAHWAY, N.J., March 30, 2023--Merck to Hold First-Quarter 2023 Sales and Earnings Conference Call on April 27
RAHWAY, N.J., March 29, 2023--FDA Converts to Full Approval Indication for KEYTRUDA for Certain Adult and Pediatric Patients With Advanced MSI-H or dMMR Solid Tumors
RAHWAY, N.J., March 27, 2023--KEYTRUDA® Plus Chemotherapy Significantly Improved PFS Compared to Chemo Alone as 1L Therapy for Advanced or Recurrent Endometrial Carcinoma
RAHWAY, N.J., March 16, 2023--Merck Provides Update from Open-Label Arm of Phase 2 KeyVibe-002 Trial Evaluating MK-7684A in Previously Treated Patients with mNSCLC
RAHWAY, N.J. & KINGSTON, Ontario, March 10, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma. IND.227 was sponsored
RAHWAY, N.J., March 08, 2023--Merck to Present at the Barclays 2023 Global Healthcare Conference
RAHWAY, N.J., March 06, 2023--Merck’s Activin Signaling Inhibitor Sotatercept Improved Six-Minute Walk Distance by 40.8 Meters at Week 24 in Adults with PAH on Background Therapy
RAHWAY, N.J., March 06, 2023--Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
RAHWAY, N.J., March 06, 2023--U.S. FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-R®II, VARIVAX®, and ProQuad®
RAHWAY, N.J., March 02, 2023--Merck and AstraZeneca Provide Update on US Regulatory Review of LYNPARZA for Use With Abiraterone and Prednisone or Prednisolone in mCRPC